Friday, August 29, 2025
32 US-listed companies reporting
| Symbol | Company | EPS Est. | Revenue Est. | Price | Market Cap | |
|---|
| BABA | Alibaba Group Holding Limited | $2.13 | 34.26B | $117.70 | 282.11B | Chart → |
| GPS | The Gap, Inc. | - | - | $24.55 | 9.21B | Chart → |
| FRO | Frontline Plc | $0.42 | 307.40M | $37.77 | 8.41B | Chart → |
| DOOO | BRP Inc. | $0.33 | 1.29B | $64.23 | 4.69B | Chart → |
| DOOO | BRP Inc. | $0.63 | 1.44B | $64.23 | 4.69B | Chart → |
| DOO | BRP Inc. | $0.34 | 1.29B | $60.87 | 4.46B | Chart → |
| CHA | Chagee Holdings Limited American Depositary Shares | $0.09 | 4.11B | $11.30 | 2.16B | Chart → |
| EOS | Eaton Vance Enhanced Equity Income Fund II | - | - | $22.20 | 1.18B | Chart → |
| PXED | Phoenix Education Partners, Inc | $0.92 | 251.90M | $30.15 | 1.08B | Chart → |
| LOTWW | Lotus Technology Inc. Warrants | - | - | $0.08 | 898.79M | Chart → |
| LOT | Lotus Technology Inc. American Depositary Shares | - | - | $1.05 | 680.54M | Chart → |
| NUTR | NUSATRIP Inc | - | - | $41.80 | 628.33M | Chart → |
| ETB | Eaton Vance Tax-Managed Buy-Write Income Fund | - | - | $15.59 | 457.80M | Chart → |
| LANV | Lanvin Group Holdings Limited | - | - | $1.35 | 157.88M | Chart → |
| IROQ | IF Bancorp, Inc. | - | - | $26.55 | 88.98M | Chart → |
| NRT | North European Oil Royalty Trust | - | - | $7.68 | 70.58M | Chart → |
| ZOOZ | ZOOZ Strategy Ltd. | $-0.47 | 295.94K | $5.10 | 41.32M | Chart → |
| CELUW | Celularity Inc. | - | - | $0.00 | 38.00M | Chart → |
| UTSI | UTStarcom Holdings Corp. | $-0.12 | 13.50M | $2.41 | 22.88M | Chart → |
| CELU | Celularity Inc. | - | - | $0.75 | 18.10M | Chart → |
| SVRE | SaverOne 2014 Ltd | $-246.24 | 648.00K | $2.49 | 6.50M | Chart → |
| CASI | CASI Pharmaceuticals, Inc. | $-0.47 | 6.28M | $0.15 | 2.33M | Chart → |
| ZOOZW | ZOOZ Strategy Ltd. | $-0.47 | 295.94K | $0.03 | 379.94K | Chart → |
Showing all 32 of 32 reporters for this date.
Data source: financialmodelingprep.com. Estimates can change before the report date — treat this as a starting point for further research, not investment advice.